Abstract
The recognition of human leukocyte antigen (HLA) molecules by specific receptors is a crucial step in the regulation of natural killer (NK) cell function. Killer cell immunoglobulin-like receptor (KIR) 3DS1 is one of the activating receptors of NK cell and is implicated in slowing disease progression in HIV infection. KIR3DS1 play an important role in the outcome of multiple diseases associated with viral infections. In contrast to the inhibitory receptor, much less is known about the ligands of KIR3DS1. In order to achieve a better understanding of the biology of KIR3DS1 and its ligand systems, it is necessary to identify the ligands of KIR3DS1. In this work, we utilized recombinant HLA-B2705 molecules and DsbA-KIR3DS1 fusion protein to monitor the interaction between HLA-B2705 complexes and DsbAKIR3DS1 using BIAcore 3000 SPR sensor and found that the specific binding between KIR3DS1 and HLA-B2705 existed and the affinity was 6.95×10-6 mol//L. So we concluded that HLA-B2705 is a possible ligand of KIR3DS1.
Keywords: HLA-B2705, peptide, Killer cell immunoglobulin-like receptor, prokaryotic expression, purification, SPR, BIAcore, affinity
Protein & Peptide Letters
Title: Kinetics of Interaction of HLA-B2705 with Natural Killer Cell Immunoglobulin- Like Receptor 3DS1
Volume: 17 Issue: 5
Author(s): Hui Li, Shun-Lin Peng, Yu Cui, Qiu-Xia Fu, Yong Zhou, Quan-Li Wang, Lin-Sheng Zhan and Sen Zhong
Affiliation:
Keywords: HLA-B2705, peptide, Killer cell immunoglobulin-like receptor, prokaryotic expression, purification, SPR, BIAcore, affinity
Abstract: The recognition of human leukocyte antigen (HLA) molecules by specific receptors is a crucial step in the regulation of natural killer (NK) cell function. Killer cell immunoglobulin-like receptor (KIR) 3DS1 is one of the activating receptors of NK cell and is implicated in slowing disease progression in HIV infection. KIR3DS1 play an important role in the outcome of multiple diseases associated with viral infections. In contrast to the inhibitory receptor, much less is known about the ligands of KIR3DS1. In order to achieve a better understanding of the biology of KIR3DS1 and its ligand systems, it is necessary to identify the ligands of KIR3DS1. In this work, we utilized recombinant HLA-B2705 molecules and DsbA-KIR3DS1 fusion protein to monitor the interaction between HLA-B2705 complexes and DsbAKIR3DS1 using BIAcore 3000 SPR sensor and found that the specific binding between KIR3DS1 and HLA-B2705 existed and the affinity was 6.95×10-6 mol//L. So we concluded that HLA-B2705 is a possible ligand of KIR3DS1.
Export Options
About this article
Cite this article as:
Li Hui, Peng Shun-Lin, Cui Yu, Fu Qiu-Xia, Zhou Yong, Wang Quan-Li, Zhan Lin-Sheng and Zhong Sen, Kinetics of Interaction of HLA-B2705 with Natural Killer Cell Immunoglobulin- Like Receptor 3DS1, Protein & Peptide Letters 2010; 17 (5) . https://dx.doi.org/10.2174/092986610791112657
DOI https://dx.doi.org/10.2174/092986610791112657 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fluorescent Molecular Imaging: Technical Progress and Current Preclinical and Clinical Applications in Urogynecologic Diseases
Current Molecular Medicine Vitamin Bs, One Carbon Metabolism and Prostate Cancer
Mini-Reviews in Medicinal Chemistry Polyketide Natural Products, Acetogenins from Graviola (Annona muricata L), its Biochemical, Cytotoxic Activity and Various Analyses Through Computational and Bio-Programming Methods
Current Pharmaceutical Design In Search of Natural Remediation for Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry Plant Ribonucleases and Nucleases as Antiproliferative Agens Targeting Human Tumors Growing in Mice
Recent Patents on DNA & Gene Sequences Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells
Mini-Reviews in Medicinal Chemistry The Role of Amitriptyline in the Management of Non-small Cell Lung Cancer
Current Cancer Therapy Reviews Exploring Mechanisms of MicroRNA Downregulation in Cancer
MicroRNA Metallopharmaceuticals in Therapy - A New Horizon for Scientific Research
Current Medicinal Chemistry Challenges and Persistent Questions in the Treatment of Trichomoniasis
Current Topics in Medicinal Chemistry Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer
Current Pharmaceutical Design System Models, Assays and Endpoint Parameters to Evaluate Anticancer Compounds During Preclinical Screening
Current Medicinal Chemistry Cisplatin and Probiotic Biomass Loaded Pessaries for the Management of Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry Identification of a Novel Intestinal First Pass Metabolic Pathway: NQO1 Mediated Quinone Reduction and Subsequent Glucuronidation
Current Drug Metabolism Pharmaceutical Applications of Graphene-based Nanosheets
Current Pharmaceutical Biotechnology Targeted Therapy of the Insulin-Like Growth Factor-1 Receptor in Cancer
Combinatorial Chemistry & High Throughput Screening Dibenzoylmethane Activates Nrf2-Dependent Detoxification Pathway and Inhibits Benzo(a)pyrene Induced DNA Adducts in Lungs
Medicinal Chemistry Zn Finger Containing Proteins as Targets for the Control of Viral Infections
Infectious Disorders - Drug Targets Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma
MicroRNA Gap Junctions as Targets for Cancer Chemoprevention and Chemotherapy
Current Drug Targets